0001130166 false 0001130166 2022-10-31 2022-10-31 0001130166 us-gaap:CommonStockMember 2022-10-31 2022-10-31 0001130166 us-gaap:PreferredStockMember 2022-10-31 2022-10-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 31, 2022

CYCLACEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 0-50626 |  | 91-1707622
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (IRS Employer Identification No.)

200 Connell Drive, Suite 1500

Berkeley Heights, NJ 07922

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (908) 517-7330

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | CYCC | The Nasdaq Stock Market LLC
Preferred Stock, $0.001 par value | CYCCP | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 | Other Events.

On October 31, 2022, Cyclacel Pharmaceuticals, Inc. (the “Company”) hosted a research and development day, whereby the Company provided a program update on its CDK2/9 inhibitor, oral fadraciclib, and oral PLK1 inhibitor, CYC140, for the treatment of advanced solid tumors and lymphoma. A copy of the slides presented are attached hereto as Exhibit 99.1 and are incorporated by reference herein.

Item 9.01 | Financial Statements and Exhibits.

(d) | Exhibits.

Exhibit No. | Description
99.1 | Slide Presentation dated October 31, 2022.
104 | Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| CYCLACEL PHARMACEUTICALS, INC.
| By: | /s/ Paul McBarron
| Name: | Paul McBarron
| Title: | Executive Vice President-Finance,
|  | Chief Financial Officer and Chief Operating Officer

Date: October 31, 2022